8-KOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Apr 16, 2018)

Filed April 16, 2018For Securities:ONCBEIGF

Summary

This 8-K filing from BeiGene, Ltd. (ONC) on April 16, 2018, announces significant progress in its clinical development pipeline. The company initiated a global Phase 2 clinical trial for its investigational anti-PD-1 antibody, tislelizumab, targeting patients with relapsed or refractory mature T- and NK-cell lymphomas. This marks an important step in advancing tislelizumab through late-stage development. Furthermore, BeiGene presented preliminary Phase 1 clinical data for its PARP inhibitor, pamiparib, in Chinese patients with advanced ovarian or triple-negative breast cancer at the 2018 AACR Annual Meeting. This data presentation offers investors early insights into the potential efficacy of pamiparib in these specific cancer indications.

Key Highlights

  • 1BeiGene initiated a global Phase 2 clinical trial for tislelizumab (anti-PD-1 antibody) in T- and NK-cell lymphomas.
  • 2The Phase 2 trial for tislelizumab is focused on patients with relapsed or refractory disease.
  • 3Preliminary Phase 1 clinical data for pamiparib (PARP inhibitor) was presented at the 2018 AACR Annual Meeting.
  • 4Pamiparib data was presented for Chinese patients with locally advanced or metastatic high-grade non-mucinous ovarian cancer or triple-negative breast cancer.
  • 5The presented pamiparib data is from patients who experienced disease progression after at least one line of chemotherapy.
  • 6The filing includes two press releases detailing these clinical development updates.
  • 7The company is actively advancing multiple investigational oncology therapies.

Frequently Asked Questions

Tislelizumab is an investigational anti-PD-1 antibody. The filing announces the initiation of a global Phase 2 clinical trial for tislelizumab in patients with relapsed or refractory mature T- and NK-cell lymphomas.

Pamiparib is an investigational PARP inhibitor. Preliminary clinical data from an ongoing Phase 1 trial of pamiparib in Chinese patients with advanced ovarian cancer or triple-negative breast cancer was presented at the 2018 AACR Annual Meeting.

The Phase 2 trial for tislelizumab is for patients with relapsed or refractory mature T- and NK-cell lymphomas. The presented pamiparib data is from Chinese patients with locally advanced or metastatic high-grade non-mucinous ovarian cancer (including fallopian cancer), or triple-negative breast cancer, who had disease progression after at least one line of chemotherapy.

No, these announcements relate to clinical trial initiations and data presentations for investigational therapies. Tislelizumab and pamiparib are not yet approved by regulatory authorities.